National Graphite Corp. is an exploration company, which engages in the exploration of gold, silver, and related minerals. The company is headquartered in Dusseldorf, Nordrhein-Westfalen. The company went IPO on 2009-06-30. The firm is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The firm operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.
